Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation

Background Exon 19 deletions and L858R point mutation are the most commonly encountered active epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), and they predict greater efficacy of gefitinib therapy. The objective of this study was to evaluate whether body sur...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2014-11, Vol.74 (5), p.939-946
Main Authors: Igawa, Satoshi, Kasajima, Masashi, Ishihara, Mikiko, Kimura, Michiko, Hiyoshi, Yasuhiro, Niwa, Hideyuki, Kusuhara, Seiichiro, Harada, Shinya, Asakuma, Maiko, Otani, Sakiko, Katono, Ken, Sasaki, Jiichiro, Masuda, Noriyuki
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Body Surface Area
Cancer Research
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Disease-Free Survival
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Mutation
Oncology
Original Article
Pharmacology. Drug treatments
Pharmacology/Toxicology
Pneumology
Protein Kinase Inhibitors - therapeutic use
Quinazolines - therapeutic use
Receptor, Epidermal Growth Factor - genetics
Retrospective Studies
Time Factors
Treatment Outcome
Tumors
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Exon 19 deletions and L858R point mutation are the most commonly encountered active epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), and they predict greater efficacy of gefitinib therapy. The objective of this study was to evaluate whether body surface area (BSA) affects the efficacy of gefitinib in patients with NSCLC harboring an active EGFR mutation. Methods We reviewed the medical records of consecutive patients with advanced NSCLC harboring an active EGFR mutation who received gefitinib monotherapy. The median BSA value was used as the cutoff value to evaluate the impact of BSA on the efficacy of gefitinib. Results The median BSA of the 103 NSCLC patients harboring an active EGFR mutation was 1.45 m 2 . The overall response rate, progression-free survival (PFS), and median survival time (MST) were 65.0 %, 11.3 months, and 26.2 months, respectively. There were no significant differences in clinical outcomes between the high-BSA group (BSA ≥ 1.45 m 2 ) and low-BSA group (BSA 
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-014-2570-1